We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the JAMA article, Steven Pearson, Franklin Miller and Ezekiel Emanuel, all of the Department of Clinical Bioethics at NIH, examine Medicare's coverage with evidence development policy, which allows certain services and treatments to be covered if patients participate in clinical trials.
Parker & Waichman, LLP announced that it has filed suit against Ortho-McNeil Pharmaceutical, Inc., a division of Johnson and Johnson
Inc., on behalf of a 34 year-old woman.
North
Carolina and 51 hospitals in the state will repay the federal government $151.5 million to account for Medicaid overpayments the state and hospitals received that were the result of accounting mistakes, according to a settlement agreement released Friday by the state's three U.S. attorneys and HHS, the Raleigh News & Observer reports.
In its upcoming term, the New Jersey Supreme Court will hear two cases that will decide the extent to which out-of-state plaintiffs suing pharmaceutical companies can reap the benefits of New Jersey's consumer-friendly statutes -- with potentially billions of dollars in damages riding on the outcome.
Discounter Wal-Mart and drugstore CVS said they are reviewing the Food and Drug Administration approval Thursday of the over-the-counter sale of its "morning-after" pill and could decide to sell it without prescription in their stores.
A federal judge in Greenbelt has thrown out a lawsuit filed by Montgomery County that sought to overturn a Food and Drug Administration decision not to allow the county to import prescription drugs from Canada for public employees.
Seattle-based biotechnology company ZymoGenetics has filed a patent suit against Bristol-Myers Squibb (BMS), asking the court to halt sales of BMS' rheumatoid arthritis drug Orencia because it infringes on certain technology patents owned by ZymoGenetics.
The FDA's approval of Barr Laboratories' controversial Plan B contraceptive has removed Senate objections to Andrew von Eschenbach's nomination to be FDA commissioner but has landed the agency in more legal trouble.